Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684179 | 0.81 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7098950 | 0.81 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5878876 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL618968 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL620183 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL620182 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL7102902 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL620767 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL618969 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL5878883 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4SLC6A4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | CHRNB2 227/4885CHRNA4 145/4885CYP2D6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.